--- a
+++ b/clusters/9knumclustersv2/clust_1084.txt
@@ -0,0 +1,32 @@
+Adequate bone marrow reserve as evidenced by:
+Bone marrow reserve which, in the clinical judgment of the Principal Investigator, is not adequate for participation in this trial.
+Patients must have adequate bone marrow reserve as evidenced by:
+Poor bone marrow reserve.
+Adequate bone marrow reserve
+Adequate organ function within  days of study registration including:\r\n* Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) >= . x ^/L
+Adequate bone marrow reserve as demonstrated by :
+Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments performed at screening.
+Patients must have adequate bone marrow reserve as evidenced by:
+Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at baseline
+Poor bone marrow reserve.
+And patients must have evidence of adequate bone marrow reserve as shown by platelet count of at least ,/mm^; however, if the cytopenias are due to extensive bone marrow involvement by CLL, patients may be included in the study
+Adequate bone marrow reserve (neutrophils > /mm and platelets > / mm)
+Adequate bone marrow reserve without transfusions defined as:
+Poor bone marrow reserve.
+Have adequate organ reserve as determined by laboratory test results obtained within  weeks prior to Study Day  as indicated below:
+Adequate bone marrow reserve as evidenced by ANC > .x^/L;Platelet > x^/L
+Adequate bone marrow reserve
+Has adequate bone marrow reserve as evidenced by:
+Subject must have adequate hematologic reserve
+Patient with glioblastoma must have adequate bone marrow and immune reserve, as documented by:
+Adequate bone marrow reserve: ANC ?/mm, platelets ?,/mm
+Have adequate bone marrow reserve and organ function at screening as follows:
+Adequate bone marrow reserve as demonstrated by
+The patient has adequate bone marrow reserve:  Absolute neutrophil count (ANC) > .  ^/L
+Patients must have adequate physiologic reserve as evidenced by:
+Patient has adequate bone marrow reserve, as evidenced by:
+Adequate bone marrow reserve as defined per protocol;
+Have adequate bone marrow reserve defined as:
+Patients who have undergone prior stem cell transplant will not be excluded from study entry as long as adequate marrow reserve is demonstrated (refer to hematologic parameters)
+Adequate bone marrow reserve
+Adequate hepatic reserve